摘要
重症肌无力(MG)是一种获得性自身免疫性神经肌肉接头疾病,主要由抗乙酰胆碱受体抗体介导,肌肉特异性受体酪氨酸激酶抗体、低密度脂蛋白受体相关蛋白4抗体及兰尼碱受体也可导致突触后膜乙酰胆碱受体稳定性下降而致病。其治疗主要包括对症治疗、免疫抑制治疗、免疫调节及胸腺切除术,免疫抑制治疗是目前MG的主要治疗手段,但长期使用糖皮质激素或非类固醇类免疫抑制剂治疗会带来不必要的不良反应及事件,为解决这一问题,现就MG免疫抑制治疗相关药物的研究进展进行综述,旨在寻找更合适的治疗方案,同时探索新兴生物制剂在MG治疗中的应用价值。
Myasthenia gravis(MG)is an acquired autoimmune neuromuscular junction disease mediated primarily by anti-acetylcholine receptor antibody.Muscle-specific receptor tyrosine kinase antibody,low density lipoprotein receptor-associated protein 4 antibody and ranine receptor can also reduce the stability of acetylcholine receptors in the postsynaptic membrane and cause disease.The treatment of myasthenia gravis mainly includes symptomatic therapy,immunosuppressive therapy,immunoregulation and thymotomy.Immunosuppressive therapy is the main treatment of MG,but the long-term use of glucocorticoid(a hormone steroid)or a nonsteroidal immunosuppressant can bring about unwanted side effects and adverse events.To solve this problem,research progress of immunosuppressive drugs for treating MG was summarized in this paper.This article aims at finding the right treatment plan and explore the application value of new biological agents in MG treatment.
作者
彭小梅
吴丽文
Peng Xiaomei;Wu Liwen(Department of Neurology,Hunan Children′s Hospital,School of Pediatrics,University of South China,Changsha 410000,China)
出处
《中华实用儿科临床杂志》
CAS
CSCD
北大核心
2023年第2期158-160,共3页
Chinese Journal of Applied Clinical Pediatrics
基金
湖湘青年英才支持计划(2021RC3117)。
关键词
重症肌无力
免疫治疗
生物制剂
Myasthenia gravis
Immunotherapy
Biological agents
